Correlation between Post-Procedure Residual Thrombus and Clinical Outcome in Deep Vein Thrombosis Patients Receiving Pharmacomechanical Thrombolysis in a Multicenter Randomized Trial.


Journal

Journal of vascular and interventional radiology : JVIR
ISSN: 1535-7732
Titre abrégé: J Vasc Interv Radiol
Pays: United States
ID NLM: 9203369

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 08 06 2020
revised: 06 07 2020
accepted: 07 07 2020
pubmed: 20 9 2020
medline: 25 11 2020
entrez: 19 9 2020
Statut: ppublish

Résumé

To evaluate relationships between immediate venographic results and clinical outcomes of pharmacomechanical catheter-directed thrombolysis (PCDT). Venograms from 317 patients with acute proximal deep vein thrombosis (DVT) who received PCDT in a multicenter randomized trial were reviewed. Quantitative thrombus resolution was assessed by independent readers using a modified Marder scale. The physician operators recorded their visual assessments of thrombus regression and venous flow. These immediate post-procedure results were correlated with patient outcomes at 1, 12, and 24 months. PCDT produced substantial thrombus removal (P < .001 for pre-PCDT vs. post-PCDT thrombus scores in all segments). At procedure end, spontaneous venous flow was present in 99% of iliofemoral venous segments and in 89% of femoral-popliteal venous segments. For the overall proximal DVT population, and for the femoral-popliteal DVT subgroup, post-PCDT thrombus volume did not correlate with 1-month or 24-month outcomes. For the iliofemoral DVT subgroup, over 1 and 24 months, symptom severity scores were higher (worse), and venous disease-specific quality of life (QOL) scores were lower (worse) in patients with greater post-PCDT thrombus volume, with the difference reaching statistical significance for the 24-month Villalta post-thrombotic syndrome (PTS) severity score (P = .0098). Post-PCDT thrombus volume did not correlate with 12-month valvular reflux. PCDT successfully removes thrombus in acute proximal DVT. However, the residual thrombus burden at procedure end does not correlate with the occurrence of PTS during the subsequent 24 months. In iliofemoral DVT, lower residual thrombus burden correlates with reduced PTS severity and possibly also with improved venous QOL and fewer early symptoms.

Identifiants

pubmed: 32948386
pii: S1051-0443(20)30587-X
doi: 10.1016/j.jvir.2020.07.010
pmc: PMC7541749
mid: NIHMS1629461
pii:
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1517-1528.e2

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR000448
Pays : United States
Organisme : NHLBI NIH HHS
ID : U54 HL112303
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL088118
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL088476
Pays : United States

Informations de copyright

Copyright © 2020 SIR. Published by Elsevier Inc. All rights reserved.

Références

J Lab Clin Med. 1977 May;89(5):1018-29
pubmed: 323387
J Vasc Surg Venous Lymphat Disord. 2017 Sep;5(5):678-687
pubmed: 28818221
Radiology. 1999 Apr;211(1):39-49
pubmed: 10189452
J Thromb Haemost. 2008 Jul;6(7):1105-12
pubmed: 18466316
J Vasc Surg. 2010 Nov;52(5):1387-96
pubmed: 20875713
Circulation. 2019 Feb 26;139(9):1162-1173
pubmed: 30586751
BMJ Open. 2013 Aug 29;3(8):e002984
pubmed: 23988361
Vasc Med. 2019 Oct;24(5):442-451
pubmed: 31354089
Circulation. 2019 Feb 26;139(9):1174-1176
pubmed: 30802168
N Engl J Med. 2017 Dec 7;377(23):2240-2252
pubmed: 29211671
Am J Emerg Med. 2006 Mar;24(2):162-6
pubmed: 16490644
Lancet Haematol. 2020 Jan;7(1):e40-e49
pubmed: 31786086
J Vasc Surg Venous Lymphat Disord. 2014 Apr;2(2):123-30
pubmed: 26993176
J Vasc Interv Radiol. 2013 Jan;24(1):17-24; quiz 26
pubmed: 23176966
Ann Intern Med. 2008 Nov 18;149(10):698-707
pubmed: 19017588
Lancet. 2012 Jan 7;379(9810):31-8
pubmed: 22172244
J Vasc Surg. 2003 Feb;37(2):410-9
pubmed: 12563215
J Thromb Haemost. 2009 May;7(5):884-8
pubmed: 19320818
J Vasc Interv Radiol. 2006 Mar;17(3):417-34
pubmed: 16567667
J Vasc Interv Radiol. 2014 Sep;25(9):1317-25
pubmed: 25000825

Auteurs

Mahmood K Razavi (MK)

St. Joseph's Hospital, Orange, California.

Amber Salter (A)

Division of Biostatistics, Washington University in St. Louis, St. Louis, Missouri.

Samuel Z Goldhaber (SZ)

Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Samantha Lancia (S)

Division of Biostatistics, Washington University in St. Louis, St. Louis, Missouri.

Susan R Kahn (SR)

Department of Medicine, McGill University, Division of Internal Medicine & Center for Clinical Epidemiology, Jewish General Hospital, Montreal, Canada.

Ido Weinberg (I)

Vascular Medicine Section, Cardiology Division, Vascular Ultrasound Core Laboratory (VasCore), Massachusetts General Hospital, Boston, Massachusetts.

Clive Kearon (C)

Department of Oncology, McMaster University, Hamilton, Canada.

Ezana M Azene (EM)

Gundersen Health System, La Crosse, Wisconsin.

Nilesh H Patel (NH)

Total Vascular Care Centers LLC, Peoria, Arizona.

Suresh Vedantham (S)

Mallinckrodt Institute of Radiology, Washington University in St. Louis, 510 S. Kingshighway Blvd., Box 8131, St. Louis, MO, 63110. Electronic address: vedanthams@wustl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH